Clinical Trial VICCHEM12103


Multi-center Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-Chop

Principal Investigator(s)

Nishitha Reddy


  • Protocol No. VICCHEM12103
  • Open Date: 12/31/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: 1 To determine a list of genes and construct a survival prediction model(s) that will predict the overall survival at 30 months in DLBCL patients prospectively treated with R-CHOP chemotherapy. 2 To determine the usefulness of biomarkers associated with the anti-tumor effects of rituximab (e.g. immunoglobulin G Fc receptor genotypes, CD 20 protein expression and gene expression profiles) to predict overall survival of DLBCL patients treated with R-CHOP therapy and followed for at least 24 months or until death. 3 To compare the ability of constructed survival models to predict survival in DLBCL.
  • Disease Sites: Lymphoma
  • Therapies: Chemotherapy - cytotoxic
  • Drugs: Cyclophosphamide (CTX); Doxorubicin; Prednisone; Rituxan; Rituximab (Rituxan); Vincristine
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT00450385
  • Secondary Protocol No: 20061138



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.